To identify genetic variants involved in prognosis of cutaneous melanoma (CM), we investigated associations of single nucleotide polymorphisms (SNPs) of genes in the integrin signaling pathway with CM survival by re-analyzing a published genomewide association study (GWAS) from The University of Texas M.D. Anderson Cancer Center (MDACC) and then validated significant SNPs in another GWAS from Harvard University. In the MDACC study, 1,148 SNPs were significantly associated with CMspecific survival (CMSS) (p 0.050 and false-positive report probability 0.20), and nine SNPs were validated in the Harvard study (p 0.050). Among these, three independent SNPs (i.e., DOCK1 rs11018104 T > A, rs35748949 C > T and PAK2 rs1718404 C > T) showed a predictive role in CMSS, with an effect-allele attributed adjusted hazards ratio [adjHR of 1.50 (95% confidence interval (CI) 5 1.18-1.90, p 5 7.46E-04), 1.53 (1.18-1.97, 1.18E-03) and 0.58 (0.45-0.76, 5.60E-05), respectively]. Haplotype analysis revealed that a haplotype carrying two risk alleles A-T in DOCK1 was associated with the poorest survival in both MDACC (adjHR 5 1.73, 95% CI 5 1.19-2.50, p 5 0.004) and Harvard (adjHR 5 1.95, 95% CI 5 1.14-3.33, p 5 0.010) studies. In addition, patients with an increasing number of unfavorable genotypes (NUGs) for these three SNPs had a poorer survival. Incorporating NUGs with clinical variables showed a significantly improved ability to classify CMSS (AUC increased from 86.8% to 88.6%, p 5 0.031). Genetic variants in the integrin signaling pathway may independently or jointly modulate the survival of CM patients. Further large, prospective studies are needed to validate these findings.
Cutaneous melanoma (CM) is the most highly invasive skin cancer worldwide. 1 Due to the increased incidence rate and the steady mortality rate, CM represents a major and growing public health burden. During the past several decades, there had been a consistent increase in the CM incidence. 2 The World Health Organization estimates that there will be 232,130 new cases of and 55,488 deaths from CM per year globally. 1 In the United States, the relative 5-year survival of CM was 91.5% from 2006 to 2012, almost the same to that in 2000 (92.0%). 2 Although several clinical characteristics are associated with CM survival, such as tumor stage, Breslow thickness and ulceration, the improvement in accurately predicting patient prognosis is still limited. 3 It has been shown that inherited host factors, such as genetic variants, are likely to play an important role in the etiology and progression of CM. 4, 5 Recently, several studies have reported that some putatively functional single nucleotide polymorphisms (SNPs) in genes involved in crucial biological pathways are indeed potentially predicting survival of CM patients by using the available genotyping data from published genome-wide association studies (GWASs). 6, 7 These reported genes are involved in pathways including the DNA damage and repair pathway, 8, 9 the Hippo pathway 10 and the Notch pathway.
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Given the cross-talks among different pathways in performing their functions, it is reasonable to believe that there are more genes in some other pathways that may potentially predict the survival of CM as well. The integrin signaling pathway consists of numerous signaling transduction networks that are primarily mediated by integrins. This active pathway participates in a variety of complex biological processes, including cell growth, differentiation, migration and tumor invasion. 12 Integrins are evolutionary conserved cell-adhesion receptors that mediate the interaction of cells with the extracellular matrix (ECM). 13 Integrins can transduce signals through the cell membrane in either direction: the extracellular binding properties of integrins are transmitted into the cell (outside-in signaling); the extracellular binding properties of integrins are modified from the inside of the cell (inside-out signaling). [14] [15] [16] The integrin signaling pathway comprises mainly 16 branches with at least 101 core genes. [17] [18] [19] [20] [21] [22] Somatic mutations of these genes are closely correlated with patient prognosis at a high frequency in a broad range of human cancers, including that of the colon and lung as well as CM. 21 
Material and Methods

Study population and genotyping data
The analysis used the GWAS dataset from MDACC as a discovery dataset and the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) from the Harvard University as a replication dataset. Patients from both studies were non-Hispanic whites. The study protocols were approved by Institutional Review Boards at both MD Anderson and Brigham and Women's Hospital with a written informed consent obtained from each of the subjects.
Discovery dataset
In the MDACC GWAS study, 858 non-Hispanic white patients with CM, who were recruited between March 1998 and August 2008 with complete demographic and prospective clinicopathological data collected from a standard life-style questionnaire and/or extracted from patient medical charts. All patients were followed up according to the standardized guidelines. 25 Genotyping was performed by the Illumina HumanOmni-Quad_v1_0_B array using the National Center for Biotechnology Information (NCBI) Database of Genotypes and Phenotypes(accession: phs000187.v1.p1). 26, 27 Genome-wide imputation was conducted with the MACH software based on the 1000 Genomes project phase I v2 CEU. 28 
Replication dataset
In the Harvard CM GWAS study, the two cohorts of NHS and HPFS were established in 1976 and 1986, respectively. All cases from HPFS/NHS were non-Hispanic whites from the Unites States. In the NHS, 90% of participants continue to complete questionnaires on their medical histories and baseline health-related information for >20 years and in the HPFS, the average follow-up rate over 10 years is > 90%. Questionnaire data collection of information on melanoma development was first carried out in the 1984 and 1986 in the NHS and HPFS, respectively. Eligible patients with histopathologically confirmed invasive melanoma were diagnosed at any time after baseline until the 2008 follow-up cycle for both cohorts. Genotyping was performed using the Illumina HumanHap610 array. Genome-wide imputation was also
What's new?
Integrins participate in signal transduction between cell membrane and extracellular matrix and play established roles in tumor cell proliferation, invasion and migration. The authors analyzed associations between variants in genes linked to integrin signaling and cutaneous melanoma survival by using datasets from two published genome-wide association studies. Three single nucleotide polymorphisms in two genes, DOCK1 and PAK2, showed predictive effects on survival, suggesting a potential role as prognostic factors for melanoma patients.
performed using the MACH software based on the 1000 Genomes Project CEU data (phase I v3, March 2012). 29, 30 There were 409 patients eligible for survival analysis. False-positive report probability
Gene and SNP selection
False-positive report probability (FPRP) is the probability of no true association between a genetic variant and disease, given a statistically significant finding. 33 The FPRP method depends on three factors: the observed p values, the prior probability of a true association of the tested genetic variant with a disease, and the statistical power of the test. In the present study, we assigned a prior probability of 0.1 to detect an HR of 2.0 for an association with genotypes and alleles of each SNP. Only the results with an FPRP value 0.2 were considered a significant association.
Statistical methods
CMSS was defined as the initial time from diagnosis to CMrelated death or the date of the last follow-up. The associations between SNPs and CMSS were obtained by multivariate Cox proportional hazards regression models performed with the GenABEL package of R software in an additive genetic model. In the MDACC dataset, adjustments included age, sex, Breslow thickness, regional/distant metastasis, ulceration of tumor and tumor cell mitotic rate. 34 In the validation analysis from the Harvard study, the available adjustments were age and sex. The multivariable stepwise Cox model including validated SNPs and clinical variables was performed to choose the independent and significant SNPs. A meta-analysis was further used to combine both discovery and replication studies. We constructed haplotypes to estimate associations of different risk genotypes with CMSS. The number of unfavorable genotypes (NUGs) was calculated as a summary score to evaluate the combined effects of all independent and significant SNPs. Kaplan-Meier survival curves and log-rank tests were also used to graphically evaluate the effects of NUGs on the cumulative probability of CMSS. The heterogeneity between the studies was assessed by using the v 2 based Q test, and p < 0.100 was considered as significant. Receiver operating characteristic (ROC) curve and time-dependent area under the curve (AUC) were illustrated from the logistic regression model to predict CMSS, and the AUC was used to assess the classification performance of the model. Statistical significance of the improvement in AUC was calculated by the Delong's test. 35 The expression quantitative trait locus (eQTL) analysis was performed by linear regression analysis using the R software using data of 373 Europeans from the 1000 Genomes Project. 29 All statistical analyses were performed by SAS software (version 9.1.3; SAS Institute, Cary, NC), unless otherwise specified.
Results
Basic characteristics of the two studies
For the illustrative purpose, Supporting Information Figure 1 provides the flowchart of study design and analyses performed in the present study. The characteristics of CM patients in the two studies have been previously described in details elsewhere. 6, 10, 36, 37 Overall, 858 patients from the MDACC study and 409 patients from the Harvard University with GWAS data were included in the current analyses (Supporting Information Table 1 ). In the MDACC study, all patients had complete clinical information (age at diagnosis, sex, tumor stage, Breslow thickness, ulceration of tumor and tumor cell mitotic rate) and GWAS data. The age of patients was between 17 and 94 years at diagnosis (52.4 6 14.4 years), and there were more men (496, 57.8%) than women (362, 42.2%). There were more patients with stages I/II (709, 82.6%) than stages III/IV (149, 17.4%). Univariate analysis indicated that age, sex, regional/ distant metastasis, Breslow thickness, ulceration, and mitotic rate were significant predictors of CMSS. In the Harvard study, only age, sex, survival outcome and genotype data were available for analysis. Eligible cases were between 34 to 87 years of age at diagnosis (61.1 6 10.8 years), the majority (82.4%) of whom were over 50 years old. Only age was significantly associated with CMSS by univariate analysis. The patients from the Harvard study had a relatively longer median follow-up time (179.0 months), compared with that for MDACC patients (81.1 months). During the follow-up, there were 95 (11.1%) and 48 (11.5%) patients died of CM in both MDACC and Harvard studies, respectively. We did not adjust for principal components in both MDACC and Harvard studies, because none of principal components was significantly associated with melanoma survival, which indicates that there were no detectable population stratification in both MDACC and Harvard studies.
Associations between SNPs in the integrin signaling pathway genes and survival of melanoma patients in both MDACC and harvard studies
In the discovery MDACC study, we first performed multivariate Cox models to assess associations of 2,596 genotyped and 15,688 imputed SNPs of the integrin signaling pathway genes with CMSS with adjustments for age, sex, regional/distant metastasis, Breslow thickness, ulceration and mitotic rate. The results showed that 1,984 SNPs were significantly associated with CMSS at p 0.05 in an additive genetic model (Fig. 1a) , and 1,148 of these 1,984 SNPs were still considered noteworthy with false positive report probability (FPRP) 0.2. Next, the associations between these 1,148 SNPs and CMSS were analyzed in the 409 CM patients from the Harvard study. Among these SNPs, nine were validated and remained statistically significantly associated with melanoma survival at p 0.05 in the Harvard study, including three SNPs in DOCK1 (dedicator of cytokinesis 1) and six SNPs in PAK2 (p21 activated kinase 2) ( Table 1 ). In the subsequent meta-analysis of these two studies, nine SNPs in DOCK1 and PAK2 genes still showed significant associations with CMSS (Table 1) .
Three independent SNPs as CM survival predictors
We further performed LD analysis of SNPs in DOCK1 and PAK2, and the LD values were obtained from Europeans of the 1000 Genomes Project. Except for rs11018104, two other SNPs (rs7099958 and rs35748949) in DOCK1 were in high LD (Fig.  1b) . For PAK2, four SNPs showed high LD with each other (rs843527, rs843533, rs35604781 and rs1718404), except for rs2461514 and rs7648479 that had low LD with the other four SNPs (Fig. 1c) . In SNPinfo and RegulomeDB for functional relevance, one SNP in DOCK1 (rs35748949) and three SNPs in PAK2 (rs843527, rs1718404 and rs35604781) were predicted to be putatively functional. Taken the overall consideration of p values, LD and predicted functions, we chose rs11018104 and rs35748949 in DOCK1 and rs1718404, rs2461514 and rs7648479 in PAK2 as the independent SNPs (Supporting Information Table 2 ). These five independent SNPs together with clinical prognostic variables were included in a multivariate stepwise Cox model. As a result, three independent SNPs (rs11018104, rs35748949 and rs1718404) remained significantly associated with CMSS at p 0.05 (Figs. 1d-1e and Supporting Information Table 3 ).
Haplotype and combined analyses of the three independent SNPs
In multivariate analyses for the three independent SNPs in the MDACC study, the risk effects of DOCK1 rs11018104 A and rs35748949 T alleles and protective effect of PAK2 rs1718404 T allele on CM survival were statistically significant in the trend test (p 5 0.013, 0.012, and 0.0004, respectively, Table 2 ). In the validation analysis of the Harvard study, similar results were observed (p 5 0.021, 0.041, and 0.048, respectively, Table 2 ). Haplotype analyses were also constructed to test the combined effects of the two SNPs in DOCK1. Four different haplotypes [ht1 (T-C), ht2 (T-T), ht3 (A-C), and ht4 (A-T)] at rs11018104 and rs35748949 positions were identified, and ht4 carrying two risk alleles A and T was associated with the poorest clinical outcome in the MDACC study (adjHR 5 1.73, 95% CI 5 1.19-2.50, p 5 0.004) and the Harvard study (adjHR 5 2.02, 95% CI 5 1.19-3.44, p 5 0.010) ( Table 2 ). To better estimate the joint effect of all the three SNPs, we combined their risk genotypes of rs11018104 TA 1 AA, rs35748949 CT 1 TT and rs1718404 CC into one variable as a genetic score for the number of unfavorable genotypes (NUGs) ( Table 3 ). The Table 1 . Combined analysis of nine validated SNPs using two published melanoma GWAS datasets Referring to reference allele/effect allele. 2 Adjusted for age, sex, Breslow's thickness, regional/distant metastasis, ulceration and mitotic rate. 3 Adjusted for age and sex. trend test showed that per-unit increase of NUGs was associated with an increased risk of death in the MDACC study (p < 0.001). In the Harvard study, a similar trend was observed in the association of NUGs and CMSS (p 5 0.010). Patients with three NUGs had a significant risk of death increased by near fivefold (adjHR 5 4.89, 95% CI 5 1.07-22.37, p 5 0.041), compared with those who had no NUG. We then divided the combined NUGs into two groups: a low-risk Group (0-1 NUGs) and a high-risk Group (2-3 NUGs). Compared with the low-risk group, the high-risk group had 2.14 fold (95% CI 5 1.36-3.37, p 5 0.001) and 1.96 fold (95% CI 5 1.06-3.60, p 5 0.031) increase risk of death associated with the risk genotypes in the MDACC study and the Harvard study, respectively (Table 3) . For the visual effect, we used Kaplan-Meier curves to depict the associations between NUGs and CMSS (Figs. 2a-2d ).
Stratified analyses for the NUG score and CMSS
Compared to those with 0-1 NUG scores, patients with 2-3 NUG scores exhibited significantly poorer survival in the presence of clinicopathologic risk factors in the stratified subgroups of > 50 years old, male, patients with regional/distant metastasis, Breslow's thickness > 1 mm, ulceration and mitotic rate > 1 mm 2 . However, no heterogeneity was observed among the subgroups (Supporting Information Table 4 ).
The ROC curve and time dependent AUC
Using multivariate logistic regression in the ROC curve and time dependent AUC, we further evaluated the NUG scores for improving the classification of 5-year CMSS. As shown in Figure 2e , the AUC of the 5-year CMSS significantly increased from 86.8% to 88.6% (p 5 0.031, DeLong's test), after adding NUGs to the model with clinical variables (i.e., age, sex, regional/distant metastasis, Breslow thickness, ulceration and mitotic rate) as classifiers. These results suggest a potential role of the unfavorable genotypes in predicting CMSS. In time-dependent AUC, the plot indicated an improved prediction performance with the adding of NUGs from the beginning of the follow-up and remaining over times (Fig. 2f) .
eQTL analyses
We evaluated correlations between SNPs and mRNA expression levels of their corresponding genes in 373 Europeans from the 1000 Genomes Project. We found that rs1718404 genotypes (CT and TT) demonstrated a significant association with a decreased mRNA expression level of PAK2 in both additive and dominant models (p 5 0.045 and p 5 0.029, respectively, Figure 3 ). However, there were no significant associations of rs11018104 and rs35748949 genotypes with DOCK1 mRNA expression levels.
Discussion
Recently, GWASs have identified several susceptibility loci for CM survival, but mainly limited to a few pathways. To the best of our knowledge, this is the first GWAS-based pathway study to assess the associations between genetic variants in the integrin signaling pathway genes and CM survival, using two published CM GWAS datasets. In the present study, we found that the three novel loci, DOCK1 rs11018104 T > A, DOCK1 rs35748949 C > T and PAK2 rs1718404 C > T, independently or jointly modulated survival of CM patients. The incorporation of NUGs of DOCK1 and PAK2 into the model with clinical prodedictors could further significantly improve the prediction of CMSS. The interaction of cell-ECM strongly affects many aspects of cellular behavior and is mediated by the most important cell surface receptor family: integrins that are heterodimeric transmembrane glycoproteins, by which the actin cytoskeleton is connected to ECM. The process of cell adhesion and other aspects of cell behavior, including cell proliferation, differentiation, migration and survival, are regulated by integrins through their ability to modulate the actin cytoskeleton. The biochemical pathways initiated by integrins have recently become an interesting and emerging area of research. 38, 39 During cell adhesion, engagement of integrins can trigger calcium fluxes, activate protein kinases and inositol lipid metabolism, change intracellular pH and Ca 21 , regulate the activity of the Rho family of small GTPases, and modulate multiple signal transduction cascades, including FAK, ERK, PI3K and MAPK. 40 Together, these aspects of the integrin signaling can explain the strong effect of integrin-mediated ability to modulate tumor growth, development, differentiation and metastasis. Studies have shown that several subunits of the integrins, such as aV and a2-a4 and b4, have been proven to be increased in primary and metastatic melanomas. 41, 42 These results have highlighted the critical role of the integrin signaling pathway in CM progression. DOCK1, located in the 10q26.13-q26.3, encodes a member of the dedicator of the cytokinesis protein family that act as guanine nucleotide exchange factors (GEF) for the small Rho family G proteins, and its GEF activity may be enhanced by ELMO1. 43 The encoded protein regulates the small GTPase Rac, thereby influencing several biological processes, including phagocytosis and cell migration. DOCK1 also acts as an oncogene involved in certain cancers, and overexpression of DOCK1 was related with poor prognosis in ovarian cancer. 44 In the present study, we found two SNPs, rs11018104 and rs35748949, in the intron region of DOCK1 to be associated with CM survival. According to the ENCODE project data from University of California Santa Cruz (UCSC), rs35748949 is located in a DNase I hypersensitive site, which represents open and active chromatins. Additional data showed that these two variants were located in the enhancer region containing histone modification marks of H3k4me1 and H3k27ac, respectively. Therefore, these two SNPs are likely affect gene expression by modifying the accessibility of chromatin during transcription. PAK2 encoding the p21 activated kinase 2 protein is located in 3q29, a core member of the well-known PAK family kinases that are effectors of the Rac and Cdc42 GTPases. PAK2 is involved in a number of hallmark biological processes, including cell proliferation, survival, mitosis, apoptosis and motility. 45, 46 These implicate that PAK2 plays a wide range of biological roles in transduction of integrin signals. As an oncogene, PAK2 mRNA expression levels were higher in melanoma tissue than in normal counterpart. 47 Recent studies have demonstrated that PAK2 is an independent prognostic predictor for patients with gastric cancer. 48 Consistent with this, in the present study, the risk genotype of rs1718404 CC was associated with an increasing PAK2 mRNA expression level. The annotation of the ENCODE project showed that rs1718404 is also located in the DNase I hypersensitive site and a region with certain level of H3K4Me1 enrichment, which suggests that rs1718404 may be involved in transcriptional activity. These provide possible scientific insights into the mechanism underlying the observed associations between these genetic variants and survival of CM patients.
Several limitations of the current study must be noted. First, compared with the MDACC survival analysis (with adjustment for age, sex, Breslow thickness, regional/distant metastasis, ulceration and mitotic rate), the adjusted information was only available for age and sex in the Harvard survival analysis. However, no heterogeneity was observed in the results from two studies. Additional analysis with other clinicopathological factors, such as systemic therapies according to the guideline of CM treatment, may provide more information that could further improve survival analysis. Second, although we demonstrated that the three genetic variants in the integrin signaling pathway genes were associated with CMSS in non-Hispanic whites, more studies with multiethnic groups on the role of these SNPs in CM patients' survival are warranted. Third, further functional investigation should be performed to provide more insights about these three SNPs identified in the present study.
The CM prognosis is a complexly dynamic process that is affected by a variety of clinicopathological factors and is likely influenced by a combination of genetic variants. The current findings suggest that genetic variants in DOCK1 (rs11018104 and rs35748949) and PAK2 (rs1718404) genes of the integrin signaling pathway may be prognostic biomarkers for CM patients, once further validated in future large, prospective studies. 
